BNET Industries
Johnson & Johnson (JNJ) is in the Pharma Industry
- Revenue
- Dec 30 2007
- $61.0B
- Profit
- Dec 30 2007
- $10.5B
- Market Cap
- Jul 17 2008
- $191.1B
Latest News and Analysis
J&J Found Not Liable in Motrin Lawsuit
LOS ANGELES (Reuters) - Johnson & Johnson on Thursday won a lawsuit brought by the family of an 11-year-old girl who became blind after using the drug Children's Motrin in 2003. The painkiller is made by Johnson & Johnson's JNJ McNeil consumer healthcare...
Johnson & Johnson a Compelling Investment
Mike Havrilla submits:Johnson & Johnson (NYSE: JNJ) 1-Year Chart vs. S&P 500 Index and Pharma HOLDRS PPH Johnson & Johnson JNJ reported record sales and profits that beat expectations for the 2Q08 before the market open yesterday. The stock has been a solid performer, illustrated in the 1-year chart above...
Some Bargain Stocks to Consider Buying
Dobromir Stoyanov submits: Ever since the broad market indexes entered into bear market territory, I have been checking the dividend champions list for bargains. I came up with a list, using the follwoing screen criteria:1) Company has consistently increased dividends for more than 25 consecutive years2) The P/E ratio is...
J&J Profit Beats Forecast, But Drug Sales Dim
By Ransdell Pierson NEW YORK (Reuters) - Johnson & Johnson JNJ on Tuesday posted second-quarter earnings that beat Wall Street expectations, as strong demand for its medical devices and consumer products overshadowed negligible growth of prescription drugs. The diversified health-care company,...
Options Trader: Tuesday Outlook
Phil Davis submits: Taking a deep breath… holding it…. and exhale. Nope, doesn’t make me feel one bit better. I’m still pissed off and I haven’t calmed down from yesterday’s rant yet but I’ll try to calm down and just be analytical now…. THIS TOTALLY SUCKS! What the...
Dividend Growth Stocks: A Salve for the Bear's Bite
Alan Brochstein, CFA submits: I have frequently written about high quality dividend growth stocks, most recently about two months ago. I seem to receive very favorable responses to those articles, but after that one, I was told by one reader than my work was "laughable." He bragged about...
Johnson & Johnson's Future Looks Bright
Devin Hobbes submits: Founded in 1886 and traded on the New York Stock Exchange since 1944, Johnson & Johnson JNJ is the largest and most diversified health care firm in the world. The company has raised dividends every year for the last 44 years. Its most recent dividend, in June,...
Johnson & Johnson Q2 2008 Earnings Call Transcript
Johnson & Johnson JNJ Q2 2008 Earnings Call
Earnings Preview: Johnson & Johnson
Johnson & Johnson JNJ is expected to report Q2 earnings before market open Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Guidance Analysts are looking for a profit of $1.12 on revenue of $15.99B. The consensus is $1.09 to $1.15 for EPS, and revenue of $15.71B...
Key Earnings Reports This Week
Hickey and Walters Bespoke submit: In the chart below, we highlight the number of companies reporting earnings on each trading day through August 8th. While things do start to pick up this week, they don't really get going until the following week. Next Thursday (the 17th) will be...
GSK to Pay Actelion Up to $3.3 Bln For Drug Rights
By Sam Cage and Sven Egenter ZURICH (Reuters) - GlaxoSmithKline Ltd GSK could pay Swiss company Actelion Ltd ATLN up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal. Glaxo, Europe's biggest drugmaker,...
Investing in Dividend Paying Companies
Devin Hobbes submits: Suppose 20 years ago, in the middle of the Savings and Loan Crisis, you decided to invest in a basket of dividend paying companies to hold for the long term. Not wanting to do too much research but still interested in buying quality companies, you decided to...
GSK to Pay Actelion Up to 1.6 Bln For Drug Rights
By Sam Cage and Sven Egenter ZURICH (Reuters UK) - GlaxoSmithKline GSK could pay Swiss company Actelion ATLN up to 3.3 billion Swiss francs (1.6 billion pounds) to develop a promising insomnia drug in the largest biotech partnering deal. Glaxo, Europe's biggest drugmaker, beat many of...
Financial Markets and the Three Bears
By Natsuko Waki LONDON (Reuters) - With the Goldilocks economy long gone, investors this week will wrestle again with the three bears of financial markets -- banking woes, slow-to-stagnant economic growth and rising inflation. On the blocks are the latest readings on inflation...
Earnings Preview: Monday through Wednesday
Trader Mark submits: As we do each earnings period, here are the names I'm watching as earnings season begins in earnest Tuesday. Nothing we own in the first batch this coming week. Thursday is the monster day of the week with a ton of interesting companies reporting.MondayGenentech DNA - the...
A Bullish Prognosis for Global Healthcare ETFs
Mike Havrilla submits:Despite concerns over the health of the domestic economy along with surging food and energy prices, the healthcare sector has failed to garner investor interest as a safe haven. Most healthcare exchange-traded funds [ETFs] and drug stocks continue to languish near multi-year lows, despite an aging Baby Boomer...
Amgen to Pay J&J $200 Million to Settle Antitrust Suit
LOS ANGELES (Reuters) - Amgen Inc AMGN said on Friday it will pay Johnson & Johnson JNJ $200 million to settle litigation alleging drug discounts offered by Amgen to cancer clinics violated antitrust laws. Amgen, the world's largest biotechnology company in terms ...
U.S. Advisers Reject Strong Epilepsy Drug Warning
By Susan Heavey BELTSVILLE, Maryland (Reuters UK) - Anti-seizure drugs used to treat epilepsy carry an increased risk of suicidal thoughts and behaviour but not enough to warrant a black box warning, a U.S. advisory panel concluded on Thursday. Members of the Food and Drug Administration's...
Dow 30 Earnings Reports
Hickey and Walters Bespoke submit: While much of the news surrounding earnings reports focuses on how much a company earns, the real test of how good or bad the report is depends on how the stock reacts. For those interested, below we highlight the percentage of up days...
Dow 30 Price Targets - Too Much Optimism?
Hickey and Walters Bespoke submit: Below we highlight the 30 stocks in the Dow Jones Industrial Average. For each one, we include its price, year-to-date change, consensus analyst price target, and the current distance from that price target. The average stock in the Dow has a...
- Next »
- page 1 of 3
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- US Market (9 results)
- Pfizer Inc. (9 results)
- Healthcare (8 results)
- 3M Co. (6 results)
- Seeking Alpha (6 results)
- Finance (6 results)
- Procter & Gamble Co. (6 results)
- United Technologies Corp. (6 results)
- Microsoft Corp. (6 results)
- Coca-Cola Co. (6 results)
- Financial Accounting (6 results)
- Earnings (5 results)
- J.P. Morgan Chase & Co. (5 results)
- Merck & Co. Inc. (5 results)
- Intel Corp. (5 results)
- Chevron Corp. (5 results)
- Exxon Mobil Corp. (5 results)
- Call Transcript (5 results)
- Hewlett-Packard Co. (4 results)
- IBM Corp. (4 results)
- McDonald's Corp. (4 results)
- Alcoa Inc. (4 results)
- AT&T Corp. (4 results)
- Boeing Co. (4 results)
- Verizon Communications Inc. (4 results)
- Management (4 results)
- Citigroup Inc. (4 results)
- Wal-Mart Stores Inc. (4 results)
- Caterpillar Inc. (4 results)
- General Electric Co. (4 results)
- General Motors Corp. (4 results)
- Bank of America Corp. (4 results)
- Home Depot Inc. (4 results)
- PepsiCo (3 results)
- Marketing (3 results)
- American International Group Inc. (3 results)
- PowerLight Corp. (3 results)
- Wells Fargo & Co. (3 results)
- GlaxoSmithKline Plc. (3 results)
- American Express Co. (3 results)
- Kraft Foods Inc. (3 results)
- Leadership (3 results)
- Google Inc. (3 results)
- E. I. Du Pont de Nemours & Co. (3 results)
- The Walt Disney Co. (3 results)
- Incorporated: 1887
- CEO: Mr. William C. Weldon
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the health care field. As of Dec 31 2007, Co. operated through three segments. Co.'s Consumer segment includes a range of products used in the baby and child care, skin care, oral and wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. Co.'s Pharmaceutical segment includes a range of products used in therapeutics areas. Co.'s Medical Devices and Diagnostics segment includes a range of products used primarily in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics.
Key Competitors
Johnson & Johnson Company Info
Board of Directors
Mr. William C. Weldon
Chairman
Mr. Charles Prince
Dr. David Satcher Ph.D.
Ms. Christine A. Poon
Vice-Chairman
Mr. James G. Cullen
Presiding Director
Dr. Mary Sue Coleman Ph.D.
Dr. Michael M. E. Johns M.D.
Mr. Arnold G. Langbo
Dr. Susan L. Lindquist Ph.D.
Mr. Leo F. Mullin
Mr. William D. Perez
Contact Information
One Johnson & Johnson Plaza
New Brunswick, NJ
732 524 0400
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
